About Us - About - AXBIO Biotechnology

Home
About
Innovation
Products

Instrument Platform

Gene Sequencing Multiplex Nucleic Acid Detection

Kits and Consumables

Kits and Consumables

Detection Kits

Multiplex DNA Analysis

Application

Microbiology Genetic Diseases Oncology Environment & Food Gene therapy

Service

Chemical Synthesis Services Bioinformatics Analysis Customized Sequencing Panels

About

Who we are

Axbio Biotechnology

As a global leader in integrated circuit biotechnology, AXBIO is committed to developing a next-generation electrochemical detection platform to transform the life sciences tools and diagnostics industry. At the intersection of IC(integrated circuits), BT(biotechnology), and AI(artificial intelligence), we are committed to creating advanced foundational platforms for life science research and clinical applications.

12 inches

Nanopore sequencing wafer in mass-production
50+

Global Patent Authorization/ Global patents granted
~ 60%

Percentage of R&D staff/ Proportion of R&D personnel
~4100㎡

GMP Production Center

Mission

Discover the source code of life, safeguard the well-being of all
Vision

To be a pioneer in building the foundational platforms of life sciences
Values

Honesty and Integrity, Result Oriented, Continuous Innovation, Resilient accountability, Teamwork

CORE TEAM

Core Team

TIAN HUI/CEO

PhD & MS, Stanford University; MS & BS, Tsinghua University, China
VP at InVisage, and Design Director at Pixim
Over 100 granted patents globally
Responsible for InVisage's quantum-dot image sensor chip (acquired by Apple) and Pixim's various image sensor products (acquired by Sony)

Igor Ivanov/COO

PhD & MS, Saint Petersburg State University, Russia
Former VP of InVisage and Intermolecular
Founder, CEO and CTO of Blue29
Served in CuTek、Mattson、AMD
Over 100 granted patents globally
Responsible for Invisage's quantum-dot process development and production, Blue29's superalloy nanomaterials and processes (acquired by KLA Tencor), CuTek's electroplating equipment (acquired by Mattson), and Intermolecular’s material development (listed on NASDAQ)

development history

Our History

2025

Completed the clinical trial of AxiLona EL-100
Launched the design and development of the ultra-high throughput EL-NGS gene sequencer AxiLona AXP-1000
Received the Class II medical device registration certificate for AxiLona EL-100 from the Jiangsu MPA

2024

AxiLona EL-100 was admitted into the Special Registration Procedures for Innovative Class II Medical Devices (commonly known as Green Path) by the Jiangsu MPA
Published peer-reviewed scientific papers and successfully completed the end-user installation of EL-NGS gene sequencer AxiLona AXP-100
Established a high-throughput protein screening system, discovered multiple producible new polymerases
AXBIO were qualified for the artificial intelligence challenge of the Innovation Nanshan 2024 Entrepreneurs Star Contest
Successfully delivered custom-synthesized chemical products

2023

Received the CE marking for AxiLona EL-100
Obtained ISO 13485:2016 certification
Launched EL-NGS gene sequencer AxiLona AXP-100 (RS, for research use only)

2022

Established our first GMP-compliant manufacturing facility in Wuxi, China
Successfully developed our non-invasive saliva glucose monitor based on electrochemical detection technology and compatible test strip, and delivered the prototype to our collaboration partner
Anxuyuan Shenzhen was recognized as a National High-tech Enterprise

2021

AXBIO was incorporated in the Cayman Islands as the holding company of our Group
Launched the product prototype of AxiLona EL-100
Launched the product prototype of EL-NGS gene sequencer AxiLona AXP-100

2020

Announced the release of engineering prototype of AxiLona EL-100.

2019

Announced the release of engineering prototype of EL-NGS gene sequencer AxiLona AXP-100

2018

Completed proprietary Bio-CMOS sequencing chip process integration.

2016

AXBIO commenced business operations

development history

Our History

团队成立

2016

AXBIO commenced business operations

扬帆起航

2018

Completed proprietary Bio-CMOS sequencing chip process integration.

产品突破

2019

Announced the release of engineering prototype of EL-NGS gene sequencer AxiLona AXP-100

技术深耕

2020

Announced the release of engineering prototype of AxiLona EL-100.

完成产品雏形

2021

AXBIO was incorporated in the Cayman Islands as the holding company of our Group
Launched the product prototype of AxiLona EL-100
Launched the product prototype of EL-NGS gene sequencer AxiLona AXP-100

迈向产业化

2022

Established our first GMP-compliant manufacturing facility in Wuxi, China
Successfully developed our non-invasive saliva glucose monitor based on electrochemical detection technology and compatible test strip, and delivered the prototype to our collaboration partner
Anxuyuan Shenzhen was recognized as a National High-tech Enterprise

全新里程碑

2023

Received the CE marking for AxiLona EL-100
Obtained ISO 13485:2016 certification
Launched EL-NGS gene sequencer AxiLona AXP-100 (RS, for research use only)

2024

AxiLona EL-100 was admitted into the Special Registration Procedures for Innovative Class II Medical Devices (commonly known as Green Path) by the Jiangsu MPA
Published peer-reviewed scientific papers and successfully completed the end-user installation of EL-NGS gene sequencer AxiLona AXP-100
Established a high-throughput protein screening system, discovered multiple producible new polymerases
AXBIO were qualified for the artificial intelligence challenge of the Innovation Nanshan 2024 Entrepreneurs Star Contest
Successfully delivered custom-synthesized chemical products

2025

Completed the clinical trial of AxiLona EL-100
Launched the design and development of the ultra-high throughput EL-NGS gene sequencer AxiLona AXP-1000
Received the Class II medical device registration certificate for AxiLona EL-100 from the Jiangsu MPA

2016

团队成立

2018

扬帆起航

2019

产品突破

2020

技术深耕

2021

完成产品雏形

2022

迈向产业化